<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01200368</url>
  </required_header>
  <id_info>
    <org_study_id>B1851056</org_study_id>
    <secondary_id>B1851056</secondary_id>
    <nct_id>NCT01200368</nct_id>
  </id_info>
  <brief_title>Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants</brief_title>
  <official_title>A Phase 3, Randomized, Active-controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given With DTaP Compared to Open-label DTaP in Healthy Japanese Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be randomly assigned to 1 of 3 groups to receive the following vaccines: Group
      1: 13-valent pneumococcal conjugate vaccine (13vPnC) and diphtheria, tetanus, and acellular
      pertussis vaccine (DTaP), Group 2: 7-valent pneumococcal conjugate vaccine (7vPnC) and DTaP,
      Group 3: DTaP alone. Group 3 subjects will also receive catch-up doses of Prevenar
      (commercial product of Prevenar in Japan) 13vPnC and 7vPnC will be blinded, and DTaP will be
      open-label. The main purpose of the study is to determine if the immune responses to 13vPnC
      are comparable to the immune responses to 7vPnC and if the immune responses to 13vPnC given
      with DTaP are comparable to those induced by DTaP given alone. In addition, the study aims to
      evaluate the side effects (safety profile) after vaccination of 13vPnC and 7vPnC when given
      with DTaP in healthy Japanese infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (&gt;=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold &gt;=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 7 Common Serotypes 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series</time_frame>
    <description>Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series</time_frame>
    <description>Predefined antibody levels were 0.1 International Units/mL (IU/mL) for diphtheria, 0.01 IU/mL for tetanus, 5 Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) for pertussis toxoid (PT), and 5 EU/mL for filamentous hemagglutinin (FHA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 6 Additional Serotypes 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series</time_frame>
    <description>Antibody GMC for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMs were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level &gt;=0.35 mcg/mL 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold &gt;=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose</time_frame>
    <description>Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose</time_frame>
    <description>Predefined antibody level was 0.1 IU/mL for diphtheria, 0.01 IU/mL for tetanus, 5 EU/mL for PT, and 5 EU/mL for FHA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibodies 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series</time_frame>
    <description>GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibodies 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series</time_frame>
    <description>GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibody 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose</time_frame>
    <description>GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibody 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose</time_frame>
    <description>GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 1 (3 to 6 Months of Age)</measure>
    <time_frame>Within 7 days after Dose 1 of the infant series</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 2 (4 to 8 Months of Age)</measure>
    <time_frame>Within 7 days after Dose 2 of the infant series</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 3 (5 to 10 Months of Age)</measure>
    <time_frame>Within 7 days after Dose 3 of the infant series</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions: Toddler Dose (12 to 15 Months of Age)</measure>
    <time_frame>Within 7 days after the toddler dose</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (3 to 6 Months of Age)</measure>
    <time_frame>Within 7 days after Dose 1 of infant series</time_frame>
    <description>Systemic events (any fever &gt;= 37.5 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 to 8 Months of Age)</measure>
    <time_frame>Within 7 days after Dose 2 of infant series</time_frame>
    <description>Systemic events (any fever &gt;= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (5 to 10 Months of Age)</measure>
    <time_frame>Within 7 days after Dose 3 of infant series</time_frame>
    <description>Systemic events (any fever &gt;= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 to 15 Months of Age)</measure>
    <time_frame>Within 7 days after the toddler dose</time_frame>
    <description>Systemic events (any fever &gt;= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">551</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine (13vPnC)</intervention_name>
    <description>0.5 mL per dose, 4 doses</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>diphtheria, tetanus, and acellular pertussis vaccine (DTaP)</intervention_name>
    <description>0.5 mL per dose, 4 doses</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent pneumococcal conjugate vaccine (7vPnC)</intervention_name>
    <description>0.5 mL per dose, 4 doses</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP</intervention_name>
    <description>0.5 mL per dose, 4 doses</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP</intervention_name>
    <description>0.5 mL per dose, 4 doses</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between 3 to 6 months of age at the enrollment.

          -  Available for the entire study period and whose parent/legal guardian can be reached
             by telephone.

          -  Healthy infant as determined by medical history, physical examination, and judgement
             of the investigator.

        Exclusion Criteria:

          -  Previous vaccination with licensed or investigational pneumococcal, diphtheria,
             tetanus, or pertussis vaccines.

          -  A previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate any type of injection.

          -  History of culture-proven invasive disease caused by S pneumoniae (eg, meningitis,
             bacteremia, osteomyelitis, arthritis).

          -  Infant who is a direct descendant (child, grandchild) of the study site personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunrise Children's Clinic</name>
      <address>
        <city>Funabashi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotobo Children's Clinic</name>
      <address>
        <city>Isumi-city</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuyama Red Cross Hospital</name>
      <address>
        <city>Matsuyama-city</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukazawa Pediatric Clinic</name>
      <address>
        <city>Higashi-ku, Fukuoka-city</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Fukuyama Medical Center</name>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kure Medical Center</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furuta Children's Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Motomachi pediatric clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakata pediatric clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenshi Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watanabe Pediatric Allergy Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshimoto Pediatrist Clinic</name>
      <address>
        <city>Kikuchi-gun</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiroko Clinic</name>
      <address>
        <city>Suzuka</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National hospital Organization Mie Chuou Medical Center</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Mie Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shibuya Clinic</name>
      <address>
        <city>Kumagaya-city</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Enomoto Clinic</name>
      <address>
        <city>Kumagaya</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakiyama Children's Clinic</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okawa Children and Family Clinic</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Child Health and Development</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seijo Sasamoto Pediatric And Allergy Clinic</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyata Pediatric Clinic</name>
      <address>
        <city>Tachikawa-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maehara Pediatric Clinic</name>
      <address>
        <city>Tama</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Clinic of Kose</name>
      <address>
        <city>Kofu</city>
        <state>Yamanashi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Bunpoukai Amemiya Clinic</name>
      <address>
        <city>Koushu-shi</city>
        <state>Yamanashi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Seijinkai Takei Clinic</name>
      <address>
        <city>Tsuru-shi</city>
        <state>Yamanashi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harada Clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Fukuoka National Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattori Pediatric Clinic</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Oukakai Sakuranbo Kodomo Clinic</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Seiaikai Seguchi Pediatric Clinic</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Momotaro Clinic</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851056&amp;StudyName=Trial%20Evaluating%20a%2013-valent%20Pneumococcal%20Conjugate%20Vaccine%20Given%20with%20diphtheria%2C%20tetanus%2C%20and%20acellular%20pertussis%20vaccine%20%28DTaP%29%20in</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <results_first_submitted>September 12, 2012</results_first_submitted>
  <results_first_submitted_qc>September 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2012</results_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>pneumococcal conjugate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC + DTaP</title>
          <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
        </group>
        <group group_id="P2">
          <title>7vPnC + DTaP</title>
          <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
        </group>
        <group group_id="P3">
          <title>DTaP (Catch-up 7vPnC)</title>
          <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="183"/>
                <participants group_id="P3" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="182"/>
                <participants group_id="P3" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="159"/>
                <participants group_id="P3" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC + DTaP</title>
          <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
        </group>
        <group group_id="B2">
          <title>7vPnC + DTaP</title>
          <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
        </group>
        <group group_id="B3">
          <title>DTaP (Catch-up 7vPnC)</title>
          <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="184"/>
            <count group_id="B3" value="184"/>
            <count group_id="B4" value="551"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="0.97"/>
                    <measurement group_id="B2" value="4.1" spread="0.97"/>
                    <measurement group_id="B3" value="4.2" spread="0.96"/>
                    <measurement group_id="B4" value="4.1" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (&gt;=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series</title>
        <description>Percentage of participants achieving predefined antibody threshold &gt;=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.</description>
        <time_frame>1 month after the infant series</time_frame>
        <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all 3 doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result after Dose 3 for the proposed analysis, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (&gt;=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series</title>
          <description>Percentage of participants achieving predefined antibody threshold &gt;=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.</description>
          <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all 3 doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result after Dose 3 for the proposed analysis, and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="94.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="96.6" lower_limit="92.7" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="94.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98.3" lower_limit="95.1" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="92.7" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="92.7" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="92.7" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="95.1" upper_limit="99.6"/>
                    <measurement group_id="O2" value="96.6" lower_limit="92.7" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="92.7" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="92.7" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95 percent (%) confidence interval (CI).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was greater than (&gt;) -0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 7 Common Serotypes 1 Month After the Infant Series</title>
        <description>Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>1 month after the infant series</time_frame>
        <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all 3 doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result after Dose 3 for the proposed analysis, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 7 Common Serotypes 1 Month After the Infant Series</title>
          <description>Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all 3 doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result after Dose 3 for the proposed analysis, and had no major protocol violations.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" lower_limit="8.48" upper_limit="10.41"/>
                    <measurement group_id="O2" value="11.54" lower_limit="10.51" upper_limit="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" lower_limit="3.90" upper_limit="5.21"/>
                    <measurement group_id="O2" value="5.71" lower_limit="4.93" upper_limit="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" lower_limit="4.52" upper_limit="5.62"/>
                    <measurement group_id="O2" value="6.80" lower_limit="6.15" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.86" lower_limit="12.16" upper_limit="15.80"/>
                    <measurement group_id="O2" value="16.79" lower_limit="15.03" upper_limit="18.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" lower_limit="4.75" upper_limit="5.91"/>
                    <measurement group_id="O2" value="7.26" lower_limit="6.53" upper_limit="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.37" lower_limit="6.43" upper_limit="8.46"/>
                    <measurement group_id="O2" value="8.38" lower_limit="7.17" upper_limit="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" lower_limit="3.16" upper_limit="4.19"/>
                    <measurement group_id="O2" value="4.53" lower_limit="3.96" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for the IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series</title>
        <description>Predefined antibody levels were 0.1 International Units/mL (IU/mL) for diphtheria, 0.01 IU/mL for tetanus, 5 Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) for pertussis toxoid (PT), and 5 EU/mL for filamentous hemagglutinin (FHA).</description>
        <time_frame>1 month after the infant series</time_frame>
        <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all 3 doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result after Dose 3 for the proposed analysis, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series</title>
          <description>Predefined antibody levels were 0.1 International Units/mL (IU/mL) for diphtheria, 0.01 IU/mL for tetanus, 5 Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) for pertussis toxoid (PT), and 5 EU/mL for filamentous hemagglutinin (FHA).</description>
          <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all 3 doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result after Dose 3 for the proposed analysis, and had no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="92.7" upper_limit="98.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis toxoid (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="92.7" upper_limit="98.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous hemagglutinin (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.6" lower_limit="92.7" upper_limit="98.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in percentage of participants achieving predefined antibody levels for diphtheria toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in percentage of participants achieving predefined antibody levels for tetanus toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in percentage of participants achieving predefined antibody levels for pertussis toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in percentage of participants achieving predefined antibody levels for filamentous hemagglutinin and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 6 Additional Serotypes 1 Month After the Infant Series</title>
        <description>Antibody GMC for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMs were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.</description>
        <time_frame>1 month after the infant series</time_frame>
        <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all 3 doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result after Dose 3 for the proposed analysis, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 6 Additional Serotypes 1 Month After the Infant Series</title>
          <description>Antibody GMC for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMs were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.</description>
          <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all 3 doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result after Dose 3 for the proposed analysis, and had no major protocol violations.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.14" lower_limit="7.23" upper_limit="9.18"/>
                    <measurement group_id="O2" value="4.53" lower_limit="3.96" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" lower_limit="4.43" upper_limit="5.42"/>
                    <measurement group_id="O2" value="4.53" lower_limit="3.96" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" lower_limit="4.14" upper_limit="5.20"/>
                    <measurement group_id="O2" value="4.53" lower_limit="3.96" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" lower_limit="4.15" upper_limit="5.34"/>
                    <measurement group_id="O2" value="4.53" lower_limit="3.96" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.26" lower_limit="7.45" upper_limit="9.17"/>
                    <measurement group_id="O2" value="4.53" lower_limit="3.96" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.56" lower_limit="7.67" upper_limit="9.56"/>
                    <measurement group_id="O2" value="4.53" lower_limit="3.96" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.50</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.54</ci_lower_limit>
            <ci_upper_limit>2.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level &gt;=0.35 mcg/mL 1 Month After the Toddler Dose</title>
        <description>Percentage of participants achieving predefined antibody threshold &gt;=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.</description>
        <time_frame>1 month after the toddler dose</time_frame>
        <population>Evaluable toddler immunogenicity set:eligible participants who received vaccine to which they were randomized at all 4 doses,had blood drawn within specified time,had &gt;=1 valid assay result after toddler dose for analysis,had no major protocol violation.N(number of participants analyzed)=participants with determinate IgG antibody level to serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level &gt;=0.35 mcg/mL 1 Month After the Toddler Dose</title>
          <description>Percentage of participants achieving predefined antibody threshold &gt;=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.</description>
          <population>Evaluable toddler immunogenicity set:eligible participants who received vaccine to which they were randomized at all 4 doses,had blood drawn within specified time,had &gt;=1 valid assay result after toddler dose for analysis,had no major protocol violation.N(number of participants analyzed)=participants with determinate IgG antibody level to serotype.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.5" upper_limit="99.8"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="96.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Difference ([13vPnC + DTaP]  [7vPnC + DTaP]) in proportions, expressed as a percentage presented along with exact 2-sided 95% CI. Difference in proportions was calculated using the serotype with the lowest proportion among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower confidence interval for the percent difference was &gt;-0.10.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose</title>
        <description>Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.</description>
        <time_frame>1 month after the toddler dose</time_frame>
        <population>Evaluable toddler immunogenicity set:eligible participants who received vaccine to which they were randomized at all 4 doses,had blood drawn within specified time,had &gt;=1 valid assay result after toddler dose for analysis,had no major protocol violation.N(number of participants analyzed)=participants with determinate IgG antibody level to serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose</title>
          <description>Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.</description>
          <population>Evaluable toddler immunogenicity set:eligible participants who received vaccine to which they were randomized at all 4 doses,had blood drawn within specified time,had &gt;=1 valid assay result after toddler dose for analysis,had no major protocol violation.N(number of participants analyzed)=participants with determinate IgG antibody level to serotype.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.34" lower_limit="13.23" upper_limit="17.79"/>
                    <measurement group_id="O2" value="16.35" lower_limit="14.19" upper_limit="18.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.05" lower_limit="14.47" upper_limit="20.08"/>
                    <measurement group_id="O2" value="13.91" lower_limit="11.93" upper_limit="16.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" lower_limit="6.11" upper_limit="8.03"/>
                    <measurement group_id="O2" value="8.64" lower_limit="7.54" upper_limit="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.70" lower_limit="17.69" upper_limit="21.93"/>
                    <measurement group_id="O2" value="20.69" lower_limit="18.25" upper_limit="23.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.10" lower_limit="6.94" upper_limit="9.47"/>
                    <measurement group_id="O2" value="9.88" lower_limit="8.64" upper_limit="11.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.73" lower_limit="14.20" upper_limit="19.71"/>
                    <measurement group_id="O2" value="9.55" lower_limit="8.11" upper_limit="11.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.64" lower_limit="7.46" upper_limit="10.01"/>
                    <measurement group_id="O2" value="10.00" lower_limit="8.61" upper_limit="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.96" lower_limit="11.94" upper_limit="16.31"/>
                    <measurement group_id="O2" value="8.64" lower_limit="7.54" upper_limit="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" lower_limit="2.17" upper_limit="2.85"/>
                    <measurement group_id="O2" value="8.64" lower_limit="7.54" upper_limit="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.10" lower_limit="9.83" upper_limit="12.53"/>
                    <measurement group_id="O2" value="8.64" lower_limit="7.54" upper_limit="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.17" lower_limit="13.31" upper_limit="17.30"/>
                    <measurement group_id="O2" value="8.64" lower_limit="7.54" upper_limit="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.90" lower_limit="9.54" upper_limit="12.45"/>
                    <measurement group_id="O2" value="8.64" lower_limit="7.54" upper_limit="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.02" lower_limit="14.07" upper_limit="18.25"/>
                    <measurement group_id="O2" value="8.64" lower_limit="7.54" upper_limit="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Ratio of IgG GMCs ([13vPnC + DTaP]/[7vPnC + DTaP]) was calculated along with 2-sided 95% CI. GMC ratio was calculated using the serotype with the lowest GMC among the 7 common serotypes in the 7vPnC + DTaP group as reference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower limit of the 2-sided, 95% CI for IgG GMC ratio was &gt;0.5.</non_inferiority_desc>
            <param_type>GMC ratio</param_type>
            <param_value>1.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.54</ci_lower_limit>
            <ci_upper_limit>2.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Toddler Dose</title>
        <description>Predefined antibody level was 0.1 IU/mL for diphtheria, 0.01 IU/mL for tetanus, 5 EU/mL for PT, and 5 EU/mL for FHA.</description>
        <time_frame>1 month after the toddler dose</time_frame>
        <population>Evaluable toddler immunogenicity population. N (number of participants analyzed) = number of participants with determinate DTaP antibody level to serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Toddler Dose</title>
          <description>Predefined antibody level was 0.1 IU/mL for diphtheria, 0.01 IU/mL for tetanus, 5 EU/mL for PT, and 5 EU/mL for FHA.</description>
          <population>Evaluable toddler immunogenicity population. N (number of participants analyzed) = number of participants with determinate DTaP antibody level to serotype.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis toxoid (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous hemagglutinin (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in percentage of participants achieving predefined antibody levels for diphtheria toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in percentage of participants achieving predefined antibody levels for tetanus toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in percentage of participants achieving predefined antibody levels for pertussis toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in percentage of participants achieving predefined antibody levels for filamentous hemagglutinin and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibodies 1 Month After the Infant Series</title>
        <description>GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.</description>
        <time_frame>1 month after the infant series</time_frame>
        <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all 3 doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result for the proposed analysis, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibodies 1 Month After the Infant Series</title>
          <description>GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.</description>
          <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all 3 doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result for the proposed analysis, and had no major protocol violations.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.94" upper_limit="1.12"/>
                    <measurement group_id="O2" value="1.10" lower_limit="0.97" upper_limit="1.25"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0.86" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.31" upper_limit="1.70"/>
                    <measurement group_id="O2" value="1.37" lower_limit="1.17" upper_limit="1.60"/>
                    <measurement group_id="O3" value="1.66" lower_limit="1.50" upper_limit="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC ratio for diphtheria toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMC ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC ratio for tetanus toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMC ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibodies 1 Month After the Infant Series</title>
        <description>GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.</description>
        <time_frame>1 month after the infant series</time_frame>
        <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all expected doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result for the proposed analysis, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibodies 1 Month After the Infant Series</title>
          <description>GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.</description>
          <population>Evaluable infant immunogenicity population: eligible participants who received the vaccine to which they were randomized at all expected doses, had blood drawn within the protocol-specified time frames, had at least 1 valid and determinate assay result for the proposed analysis, and had no major protocol violations.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis toxoid (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.12" lower_limit="60.45" upper_limit="72.32"/>
                    <measurement group_id="O2" value="57.26" lower_limit="49.23" upper_limit="66.60"/>
                    <measurement group_id="O3" value="67.64" lower_limit="62.87" upper_limit="72.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous hemagglutinin (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.30" lower_limit="56.59" upper_limit="68.59"/>
                    <measurement group_id="O2" value="53.86" lower_limit="47.27" upper_limit="61.37"/>
                    <measurement group_id="O3" value="67.48" lower_limit="61.64" upper_limit="73.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC ratio for pertussis toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMC ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC ratio for filamentous hemagglutinin and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMC ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibody 1 Month After the Toddler Dose</title>
        <description>GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.</description>
        <time_frame>1 month after the toddler dose</time_frame>
        <population>Evaluable toddler immunogenicity population. N (number of participants analyzed) = number of participants with determinate DTaP antibody level to serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibody 1 Month After the Toddler Dose</title>
          <description>GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.</description>
          <population>Evaluable toddler immunogenicity population. N (number of participants analyzed) = number of participants with determinate DTaP antibody level to serotype.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" lower_limit="2.43" upper_limit="2.90"/>
                    <measurement group_id="O2" value="3.18" lower_limit="2.94" upper_limit="3.45"/>
                    <measurement group_id="O3" value="2.63" lower_limit="2.39" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" lower_limit="2.56" upper_limit="3.28"/>
                    <measurement group_id="O2" value="2.60" lower_limit="2.29" upper_limit="2.95"/>
                    <measurement group_id="O3" value="2.89" lower_limit="2.58" upper_limit="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC ratio for diphtheria toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMC ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC ratio for tetanus toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMC ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibody 1 Month After the Toddler Dose</title>
        <description>GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.</description>
        <time_frame>1 month after the toddler dose</time_frame>
        <population>Evaluable toddler immunogenicity population. N (number of participants analyzed) = number of participants with determinate DTaP antibody level to serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibody 1 Month After the Toddler Dose</title>
          <description>GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.</description>
          <population>Evaluable toddler immunogenicity population. N (number of participants analyzed) = number of participants with determinate DTaP antibody level to serotype.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis toxoid (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.46" lower_limit="130.68" upper_limit="159.68"/>
                    <measurement group_id="O2" value="135.65" lower_limit="124.16" upper_limit="148.21"/>
                    <measurement group_id="O3" value="150.21" lower_limit="136.20" upper_limit="165.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous hemagglutinin (FHA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.68" lower_limit="130.94" upper_limit="157.66"/>
                    <measurement group_id="O2" value="141.19" lower_limit="129.20" upper_limit="154.30"/>
                    <measurement group_id="O3" value="180.31" lower_limit="163.12" upper_limit="199.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC ratio for pertussis toxoid and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMC ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC ratio for filamentous hemagglutinin and corresponding 2-sided 95% CI were calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>GMC ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 1 (3 to 6 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after Dose 1 of the infant series</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N' (number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any local reaction. 'n'=participants reporting yes for at least 1 day or no for all days for the specified local reaction for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 1 (3 to 6 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N' (number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any local reaction. 'n'=participants reporting yes for at least 1 day or no for all days for the specified local reaction for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness- Any (n=171, 172, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5"/>
                    <measurement group_id="O2" value="55.8"/>
                    <measurement group_id="O3" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Mild (n=170, 172, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2"/>
                    <measurement group_id="O2" value="51.2"/>
                    <measurement group_id="O3" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Moderate (n=164, 166, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                    <measurement group_id="O2" value="18.1"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Severe (n=161, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.6"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Any (n=168, 168, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1"/>
                    <measurement group_id="O2" value="35.7"/>
                    <measurement group_id="O3" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Mild (n= 168, 168, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="31.5"/>
                    <measurement group_id="O3" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Moderate (n=162, 165, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="12.7"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- severe (n=161, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.6"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Any (n=163, 164, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Significant (n=161, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local reaction (n=175, 174, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                    <measurement group_id="O2" value="60.9"/>
                    <measurement group_id="O3" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 2 (4 to 8 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after Dose 2 of the infant series</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N' (number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any local reaction. 'n'=participants reporting yes for at least 1 day or no for all days for the specified local reaction for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 2 (4 to 8 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N' (number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any local reaction. 'n'=participants reporting yes for at least 1 day or no for all days for the specified local reaction for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness- Any (n= 166, 168, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7"/>
                    <measurement group_id="O2" value="61.9"/>
                    <measurement group_id="O3" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Mild (n= 166, 167, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0"/>
                    <measurement group_id="O2" value="56.9"/>
                    <measurement group_id="O3" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Moderate (n= 157, 159, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="27.0"/>
                    <measurement group_id="O3" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Severe (n= 157, 154, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Any (n= 160, 171, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1"/>
                    <measurement group_id="O2" value="50.9"/>
                    <measurement group_id="O3" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Mild (n= 160, 170, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="48.2"/>
                    <measurement group_id="O3" value="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Moderate (n= 157, 157, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="17.8"/>
                    <measurement group_id="O3" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- severe (n= 157, 154, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Any (n= 159, 154, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Significant (n= 157, 154, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local reaction (n=167, 173, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3"/>
                    <measurement group_id="O2" value="67.1"/>
                    <measurement group_id="O3" value="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 3 (5 to 10 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after Dose 3 of the infant series</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N' (number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any local reaction. 'n'=participants reporting yes for at least 1 day or no for all days for the specified local reaction for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 3 (5 to 10 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N' (number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any local reaction. 'n'=participants reporting yes for at least 1 day or no for all days for the specified local reaction for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness- Any (n= 168, 162, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="51.2"/>
                    <measurement group_id="O3" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Mild (n= 167, 160, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3"/>
                    <measurement group_id="O2" value="43.1"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Moderate (n= 152, 154, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1"/>
                    <measurement group_id="O2" value="22.1"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Severe (n= 149, 152, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Any (n= 164, 157, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9"/>
                    <measurement group_id="O2" value="37.6"/>
                    <measurement group_id="O3" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Mild (n= 164, 156, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="34.0"/>
                    <measurement group_id="O3" value="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Moderate (n= 150, 154, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- severe (n= 149, 152, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Any (n= 153, 155, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Significant (n= 149, 152, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local reaction (n=171, 163, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0"/>
                    <measurement group_id="O2" value="55.8"/>
                    <measurement group_id="O3" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Toddler Dose (12 to 15 Months of Age)</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after the toddler dose</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N' (number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any local reaction. 'n'=participants reporting yes for at least 1 day or no for all days for the specified local reaction for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Toddler Dose (12 to 15 Months of Age)</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N' (number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any local reaction. 'n'=participants reporting yes for at least 1 day or no for all days for the specified local reaction for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness- Any (n= 148, 152, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                    <measurement group_id="O2" value="57.2"/>
                    <measurement group_id="O3" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Mild (n= 148, 151, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="47.7"/>
                    <measurement group_id="O3" value="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Moderate (n= 141, 139, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness- Severe (n= 140, 136, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Any (n= 149, 144, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0"/>
                    <measurement group_id="O2" value="45.8"/>
                    <measurement group_id="O3" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Mild (n= 147, 143, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="42.0"/>
                    <measurement group_id="O3" value="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- Moderate (n= 143, 138, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling- severe (n= 140, 136, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Any (n= 142, 140 ,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness- Significant (n= 140, 136, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local reaction (n=153, 152, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6"/>
                    <measurement group_id="O2" value="61.8"/>
                    <measurement group_id="O3" value="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (3 to 6 Months of Age)</title>
        <description>Systemic events (any fever &gt;= 37.5 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after Dose 1 of infant series</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N'(number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any systemic reaction. 'n'=participants reporting yes for at least 1 day or no for all days for specified systemic reaction for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (3 to 6 Months of Age)</title>
          <description>Systemic events (any fever &gt;= 37.5 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N'(number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any systemic reaction. 'n'=participants reporting yes for at least 1 day or no for all days for specified systemic reaction for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=37.5,=&lt;39 degrees C (n=168, 168, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                    <measurement group_id="O2" value="33.9"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39,=&lt;40 degrees C (n=161, 163, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=161, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=163, 163, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=165, 164, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="16.5"/>
                    <measurement group_id="O3" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=170, 165, 165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="26.7"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=164, 169, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="21.3"/>
                    <measurement group_id="O3" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives- urticaria (n=161, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of antipyretic medication (n= 161, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic event (n=177, 174, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0"/>
                    <measurement group_id="O2" value="59.8"/>
                    <measurement group_id="O3" value="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 to 8 Months of Age)</title>
        <description>Systemic events (any fever &gt;= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after Dose 2 of infant series</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N'(number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any systemic reaction. 'n'=participants reporting yes for at least 1 day or no for all days for specified systemic reaction for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 to 8 Months of Age)</title>
          <description>Systemic events (any fever &gt;= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N'(number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any systemic reaction. 'n'=participants reporting yes for at least 1 day or no for all days for specified systemic reaction for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=37.5, =&lt;39 degrees C (n=166, 161, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="36.6"/>
                    <measurement group_id="O3" value="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39, =&lt;40 degrees C (n=158, 155, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=157, 154, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=158, 159, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="14.5"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=162, 155, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="18.7"/>
                    <measurement group_id="O3" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=163, 158, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="22.2"/>
                    <measurement group_id="O3" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=161, 157, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="12.1"/>
                    <measurement group_id="O3" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives- urticaria (n=157, 154, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of antipyretic medication (n=160, 155, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic event (n=170, 169, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2"/>
                    <measurement group_id="O2" value="57.4"/>
                    <measurement group_id="O3" value="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (5 to 10 Months of Age)</title>
        <description>Systemic events (any fever &gt;= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after Dose 3 of infant series</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N'(number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any systemic reaction. 'n'=participants reporting yes for at least 1 day or no for all days for specified systemic reaction for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (5 to 10 Months of Age)</title>
          <description>Systemic events (any fever &gt;= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N'(number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any systemic reaction. 'n'=participants reporting yes for at least 1 day or no for all days for specified systemic reaction for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=37.5, =&lt;39 degrees C (n=162, 161, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39, =&lt;40 degrees C (n=150, 152, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=149, 152, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=152, 155, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9"/>
                    <measurement group_id="O2" value="9.7"/>
                    <measurement group_id="O3" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=154, 156, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="14.7"/>
                    <measurement group_id="O3" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=151, 157, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n= 154, 156, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="12.8"/>
                    <measurement group_id="O3" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives- urticaria (n= 149, 152, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of antipyretic medication (n=150, 153, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic event (n=168, 164, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 to 15 Months of Age)</title>
        <description>Systemic events (any fever &gt;= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after the toddler dose</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N'(number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any systemic reaction. 'n'=participants reporting yes for at least 1 day or no for all days for specified systemic reaction for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) subcutaneously followed by 2 single 0.5 mL doses of 13vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 13vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) subcutaneously administered concomitantly with each 13vPnC dose.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL dose of 7-valent pneumococcal conjugate vaccine (7vPnC) subcutaneously followed by 2 single 0.5 mL doses of 7vPnC subcutaneously, 4 to 8 weeks after each previous dose (infant series) and a single 0.5 mL dose of 7vPnC subcutaneously at 12 to 15 months of age (toddler dose). A single 0.5 mL dose of DTaP subcutaneously administered concomitantly with each 7vPnC dose.</description>
          </group>
          <group group_id="O3">
            <title>DTaP (Catch-up 7vPnC)</title>
            <description>Participants at 3 to 6 months of age received a single 0.5 mL DTaP dose subcutaneously followed by 2 single 0.5 mL DTaP doses subcutaneously, 4 to 8 weeks after each previous dose (infant series). Four to 6 weeks post-infant series, 2 single catch-up (CU) doses of 7vPnC (Prevenar) were administered subcutaneously, 4 to 6 weeks apart. A single 0.5 mL DTaP dose subcutaneously at 12 to 15 months of age (toddler dose) followed by a single CU dose of 7vPnC (Prevenar) subcutaneously 4 to 6 weeks post-toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 to 15 Months of Age)</title>
          <description>Systemic events (any fever &gt;= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety population included all participants who received at least 1 dose of study vaccine. 'N'(number of participants analyzed)=participants reporting yes for at least 1 day or no for all days for any systemic reaction. 'n'=participants reporting yes for at least 1 day or no for all days for specified systemic reaction for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever &gt;=37.5, =&lt;39 degrees C (n=145, 146, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0"/>
                    <measurement group_id="O2" value="49.3"/>
                    <measurement group_id="O3" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39, =&lt;40 degrees C (n=141, 136, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=139, 137, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=143, 141, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="19.9"/>
                    <measurement group_id="O3" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=143, 141, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                    <measurement group_id="O2" value="21.3"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=145, 142, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=142, 137, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="9.5"/>
                    <measurement group_id="O3" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives- urticaria (n=140, 136, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of antipyretic medication (n=141, 138, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="9.4"/>
                    <measurement group_id="O3" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic event (n=148, 152, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8"/>
                    <measurement group_id="O2" value="63.8"/>
                    <measurement group_id="O3" value="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs/SAEs: recorded from signing of informed consent form to completion of study. Participants recorded pre-specified AEs in electronic diary:local reactions; systemic events; use of antipyretic medication (up to 7 days after each vaccine dose).</time_frame>
      <desc>Safety population: participants who receive at least 1 dose of study vaccine. SAEs and AEs were grouped by system organ class and summarized. AEs included solicited AEs collected in electronic diary (local and systemic reactions; systematic assessment) and unsolicited events collected on case report form at each visit (nonsystematic assessment).</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC + DTaP - Infant Series</title>
          <description>Participants who received 3 single 0.5 mL doses of 13vPnC subcutaneously 4 to 8 weeks apart along with 3 single 0.5 mL doses of DTaP subcutaneously (infant series), assessed from Infant Dose 1 through the blood draw 28 to 42 days post-infant series.</description>
        </group>
        <group group_id="E2">
          <title>7vPnC + DTaP - Infant Series</title>
          <description>Participants who received 3 single 0.5 mL doses of 7vPnC subcutaneously 4 to 8 weeks apart along with 3 single 0.5 mL doses of DTaP subcutaneously (infant series), assessed from Infant Dose 1 through the blood draw 28 to 42 days post-infant series.</description>
        </group>
        <group group_id="E3">
          <title>DTaP (Catch-up 7vPnC) - Infant Series</title>
          <description>Participants who received 3 single 0.5 mL DTaP doses subcutaneously 4 to 8 weeks apart (infant series) followed by 2 single catch-up (CU) doses, CU Dose 1 and CU Dose 2 (separated by 4 to 6 weeks), of 7vPnC (Prevenar) 4 to 6 weeks post-infant series, assessed from Infant Dose 1 through the CU Dose 1.</description>
        </group>
        <group group_id="E4">
          <title>13vPnC + DTaP - After the Infant Series</title>
          <description>Participants who received 3 single 0.5 mL doses of 13vPnC subcutaneously 4 to 8 weeks apart along with 3 single 0.5 mL doses of DTaP subcutaneously (infant series), assessed after the infant series blood draw to the toddler dose.</description>
        </group>
        <group group_id="E5">
          <title>7vPnC + DTaP - After the Infant Series</title>
          <description>Participants who received 3 single 0.5 mL doses of 13vPnC subcutaneously 4 to 8 weeks apart along with 3 single 0.5 mL doses of DTaP subcutaneously (infant series), assessed after the infant series blood draw to the toddler dose.</description>
        </group>
        <group group_id="E6">
          <title>DTaP (Catch-up 7vPnC) - After the Infant Series</title>
          <description>Participants who received 3 single 0.5 mL DTaP doses subcutaneously 4 to 8 weeks apart (infant series) followed by 2 single catch-up (CU) doses, CU Dose 1 and CU Dose 2 (separated by 4 to 6 weeks), of 7vPnC (Prevenar) 4 to 6 weeks post-infant series, assessed after CU Dose 1 to the toddler dose.</description>
        </group>
        <group group_id="E7">
          <title>13vPnC + DTaP - Toddler Dose</title>
          <description>Participants who received a single 0.5 mL dose of 13vPnC subcutaneously (toddler dose) along with 0.5 mL dose of DTaP subcutaneously, assessed from the toddler dose through the blood draw 28 to 42 days post-toddler dose.</description>
        </group>
        <group group_id="E8">
          <title>7vPnC + DTaP - Toddler Dose</title>
          <description>Participants who received a single 0.5 mL dose of 7vPnC subcutaneously (toddler dose) along with 0.5 mL dose of DTaP subcutaneously, assessed from the toddler dose through the blood draw 28 to 42 days post-toddler dose.</description>
        </group>
        <group group_id="E9">
          <title>DTaP (Catch-up 7vPnC) - Toddler Dose</title>
          <description>Participants who received a single 0.5 mL DTaP dose subcutaneously (toddler dose) followed by a single catch-up (CU) dose (CU Dose 3) of 7vPnC (Prevenar) 4 to 6 weeks after toddler dose; assessed from toddler dose through the CU Dose 3.</description>
        </group>
        <group group_id="E10">
          <title>DTaP (Catch-up 7vPnC) - After the Toddler Dose</title>
          <description>Participants who received a single 0.5 mL DTaP dose subcutaneously (toddler dose) followed by a single catch-up (CU) dose (CU Dose 3) of 7vPnC (Prevenar) 4 to 6 weeks after toddler dose; assessed after the CU Dose 3 to 28 to 42 days post-CU Dose 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness bilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Mycoplasma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neuritis cranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="160" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="155" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="147" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="104" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="99" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="112" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="105" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acetonaemic vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Injection site dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vaccination site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vaccination site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=37.5, =&lt;39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="71" subjects_at_risk="145"/>
                <counts group_id="E8" subjects_affected="72" subjects_at_risk="146"/>
                <counts group_id="E9" subjects_affected="46" subjects_at_risk="146"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=37.5, =&lt;39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="155"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=37.5, =&lt;39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="161"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=39, =&lt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=39, =&lt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;=39, =&lt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="143"/>
                <counts group_id="E8" subjects_affected="28" subjects_at_risk="141"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="143"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="143"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="141"/>
                <counts group_id="E9" subjects_affected="24" subjects_at_risk="144"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="145"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="142"/>
                <counts group_id="E9" subjects_affected="23" subjects_at_risk="143"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="158"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="167"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="142"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="137"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="141"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Hives (urticaria)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Hives (urticaria)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Hives (urticaria)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Use of antipyretic medication to treat symptoms</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="138"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Use of antipyretic medication to treat symptoms</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Use of antipyretic medication to treat symptoms</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Adenoviral conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Anal fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Echo virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Erythema infectiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gianotti-Crosti syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="21" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="28" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="27" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Omphalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pneumococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="62" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="28" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="25" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Chillblains</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Ear injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Frostbite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body height below normal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuritis cranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Genital labial adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Posthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Fibrinous bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Infantile asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pulmonary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Asteatosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Eczema infantile</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis palmaris and plantaris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Onychomadesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pityriasis rosea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="92" subjects_at_risk="148"/>
                <counts group_id="E8" subjects_affected="87" subjects_at_risk="152"/>
                <counts group_id="E9" subjects_affected="52" subjects_at_risk="149"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="172"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="74" subjects_at_risk="148"/>
                <counts group_id="E8" subjects_affected="72" subjects_at_risk="151"/>
                <counts group_id="E9" subjects_affected="42" subjects_at_risk="148"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="39" subjects_at_risk="141"/>
                <counts group_id="E8" subjects_affected="38" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="145"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="73" subjects_at_risk="149"/>
                <counts group_id="E8" subjects_affected="66" subjects_at_risk="144"/>
                <counts group_id="E9" subjects_affected="39" subjects_at_risk="148"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="147"/>
                <counts group_id="E8" subjects_affected="60" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="33" subjects_at_risk="146"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="143"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="138"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="146"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="163"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="142"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="155"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

